Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naltrexone + memantine is a combination drug composed of naltrexone, an opioid receptor antagonist, and memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist. This combination targets both the opioid and glutamate neurotransmitter systems, which play important roles in alcohol drinking behaviors. Naltrexone blocks opioid receptors to reduce the rewarding effects of alcohol, while memantine modulates glutamatergic signaling by antagonizing NMDA receptors. Clinical studies have shown that adding memantine (20 mg/day) to naltrexone (50 mg/day) enhances efficacy in reducing alcohol consumption and craving compared to naltrexone alone among heavy drinkers with a family history of alcoholism. The beneficial effects appear to persist even after discontinuation of memantine treatment. This combination is primarily investigated for treating alcohol use disorder.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naltrexone + memantine.